Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Gregory Stallworth

Emergency Medicine Holly Springs, MS Medical Doctor

NPI 1043314057 CMS profile 1566

1430 Hwy 4-East, Holly Springs, MS 38634

Open in the dashboard

General payments

$2,040

128 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Gregory Stallworth of Holly Springs, MS is reported in the CMS Open Payments database as having received $2,040 across 128 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 95th percentile of Emergency Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $148 8
2024 General $136 8
2023 General $153 9
2022 General $421 25
2021 General $458 31
2020 General $352 24
2019 General $371 23

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Gregory Stallworth
  • Emergency Medicine median
  • Middle half of Emergency Medicine
  • National median

In program year 2025, general payments to Gregory Stallworth were reported at $148. Among 10,690 Emergency Medicine profiles paid that year, the median was $57 and the middle half received between $24 and $150.

Show as a table
Year Gregory Stallworth Emergency Medicine median Middle half National median
2019 $371 $51 $18–$128 $163
2020 $352 $29 $16–$99 $114
2021 $458 $40 $18–$124 $132
2022 $421 $49 $20–$134 $149
2023 $153 $51 $22–$142 $160
2024 $136 $52 $22–$150 $164
2025 $148 $57 $24–$150 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Novo Nordisk Inc $470 32 payments
  2. AstraZeneca Pharmaceuticals LP $247 15 payments
  3. Novartis Pharmaceuticals Corporation $221 15 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $221 13 payments
  5. Janssen Biotech, Inc. $200 14 payments
  6. Abbott Laboratories $140 8 payments
  7. Amarin Pharma Inc. $66 3 payments
  8. Janssen Pharmaceuticals, Inc $61 4 payments
  9. Sunovion Pharmaceuticals Inc. $60 4 payments
  10. Kowa Pharmaceuticals America, Inc. $53 2 payments
  11. Other $299 18 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,040 128 payments
Products named General payments · program years 2019–2025
  1. Ozempic $434 30 payments
  2. RYBELSUS $326 24 payments
  3. FARXIGA $230 14 payments
  4. Kerendia $221 13 payments
  5. SYMTUZA $200 14 payments
  6. ENTRESTO $131 9 payments
  7. FreeStyle Libre 2 $87 5 payments
  8. LEQVIO $74 5 payments
  9. XARELTO $61 4 payments
  10. LONHALA MAGNAIR $60 4 payments
  11. Other $743 43 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 145 drugs

Part D claims

8,078

Median for Emergency Medicine: 88

Drug cost

$414,981

Median for Emergency Medicine: $590

Branded share of claims

21.2%

Median for Emergency Medicine: 33.8%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Ozempic Semaglutide Brand 41 $48,494
Linzess Linaclotide Brand 78 $47,816
Rybelsus Semaglutide Brand 39 $43,672
Eliquis Apixaban Brand 55 $37,944
Entresto Sacubitril/Valsartan Brand 42 $28,650
Vraylar Cariprazine Hcl Brand 13 $18,501
Tradjenta Linagliptin Brand 26 $17,305
Xarelto Rivaroxaban Brand 26 $16,688
Trintellix Vortioxetine Hydrobromide Brand 28 $12,858
Basaglar Kwikpen U-100 Insulin Glargine,hum.Rec.Anlog Brand 32 $11,911

The 10 drugs with the highest cost, of 145 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 40,243 Part D prescribers listed as Emergency Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

3 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
Kerendia
  • Bayer HealthCare Pharmaceuticals Inc. $63
$63 — —
Ozempic
  • Novo Nordisk Inc $38
$38 41 —
RYBELSUS
  • Novo Nordisk Inc $18
$18 39 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

128 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Emergency Medicine in Mississippi

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record